Get started
Author

Lizette Moros

Observed names: L Moros, L. Moros
Observed institution: Boehringer Ingelheim (Germany)
OpenAlex ID: A5021458082
Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: data from the INBUILD trial
2023 · Eric L. Matteson, Martin Aringer, et al. · Clinical Rheumatology · 87
PDF
Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials
2019 · Imre Noth, Marlies Wijsenbeek, et al. · European Respiratory Journal · 46
PDF
Collaboration between patient organisations and a clinical research sponsor in a rare disease condition: learnings from a community advisory board and best practice for future collaborations
2020 · Annelise Roennow, Maureen Sauvé, et al. · BMJ Open · 28
PDF
Things left unsaid: important topics that are not discussed between patients with systemic sclerosis, their carers and their healthcare professionals—a discourse analysis
2020 · Christopher P. Denton, Bee Laird, et al. · Clinical Rheumatology · 11
PDF
Challenges in physician-patient communication for optimal management of systemic sclerosis-associated interstitial lung disease: a discourse analysis
2020 · Christopher P. Denton, Bee Laird, et al. · Clinical Rheumatology · 10
PDF
Op0124 Effects of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease Associated With Rheumatoid Arthritis (ra-ild) in the Inbuild Trial
2021 · C. Kelly, E. Matteson, et al. · Annals of the Rheumatic Diseases · 6
Sat0345 Is There a Difference Between the Sexes in the Rate of Progression of Systemic Sclerosis-associated Ild (ssc-ild)? Data From the Senscis Trial
2020 · E. Volkmann, S. Vettori, et al. · Annals of the Rheumatic Diseases · 5
Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials
2018 · J Behr, I Noth, et al. · Pneumologie · 3
M34 Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the tomorrow and inpulsis trials
2017 · I Noth, M Wijsenbeek, et al. · Thorax · 2
PDF
Interstitial lung disease awareness among patients with connective tissue diseases: an international survey
2026 · Oliver Distler, Katy Antonopoulou, et al. · EULAR Rheumatology Open · 1
PDF
Effect of Nintedanib on Decline in Forced Vital Capacity (FVC) in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) by GAP Stage and ILD-GAP Index
2021 · M. Kreuter, K.B. Highland, et al. · American Journal of Respiratory and Critical Care Medicine · 1
PDF
Pare0009 Community Advisory Board Input Can Make Lay Summaries of Clinical Trial Results More Understandable
2020 · J. Welling, A. Roennow, et al. · Annals of the Rheumatic Diseases · 1
PDF
Plain Language Summary of the Manuscript: Interstitial lung disease awareness among patients with connective tissue diseases: an international survey
2026 · Oliver Distler, Katy Antonopoulou, et al. · Boehringer Ingelheim
Plain Language Summary of the Manuscript: Patient reports of evaluations for interstitial lung disease in patients with connective tissue diseases and rheumatoid arthritis: An international survey
2026 · Oliver Distler, Katy Antonopoulou, et al. · Boehringer Ingelheim
Patient reports of evaluations for interstitial lung disease in patients with connective tissue diseases and rheumatoid arthritis: an international survey
2026 · Oliver Distler, Katy Antonopoulou, et al. · Respiratory Research
Patient reports of evaluations for interstitial lung disease in patients with connective tissue diseases and rheumatoid arthritis: an international survey
2026 · Oliver Distler, Katy Antonopoulou, et al. · Figshare
Additional file 1 of Patient reports of evaluations for interstitial lung disease in patients with connective tissue diseases and rheumatoid arthritis: an international survey
2026 · Oliver Distler, Katy Antonopoulou, et al. · Figshare
Additional file 2 of Patient reports of evaluations for interstitial lung disease in patients with connective tissue diseases and rheumatoid arthritis: an international survey
2026 · Oliver Distler, Katy Antonopoulou, et al. · Figshare
Novel clustering approach to understanding distinct phenotypes of patients with systemic sclerosis
2026 · Dinesh Khanna, Mario Ehlers, et al. · Journal of Scleroderma and Related Disorders
P.402 Understanding care experiences in systemic sclerosis: physician and patient perspectives stratified by clinical clusters
2026 · Francesco Del Galdo, Mario Ehlers, et al. · Poster presentations
P.382 Mapping the journey to diagnosis in systemic sclerosis: a real-world cluster-based analysis
2026 · Dinesh Khanna, Mario Ehlers, et al. · Poster presentations
Effects of nintedanib in patients with progressive fibrosing interstitial lung disease associated with rheumatoid arthritis (RA-ILD) in the INBUILD trial*
2022 · D Koschel, C Kelly, et al. · Pneumologie
Effets du nintédanib chez des patients atteints de pneumopathie interstitielle diffuse (PID) fibrosante progressive associée à la polyarthrite rhumatoïde (PR) dans l’étude INBUILD
2021 · C. Kelly, E. Matteson, et al. · Revue du Rhumatisme
Works count: 23
Citation count: 197
H-index: 6
I10-index: 5
Year
Topic
Type